Comparative Renal Function of Young (18-45 Years) and Ageing (55 Years and Above) Kidney Donors
NCT ID: NCT00846729
Last Updated: 2018-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120 participants
OBSERVATIONAL
2003-03-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is also our purpose with this study to refine the tests to be used in the donor evaluation process so as to accurately identify ideal candidates for safe kidney donation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers of Aging as Predictors of Kidney Transplant Function
NCT02335333
The Study of Long-term Deterioration of Kidney Transplants.
NCT00217126
The Outcomes of Living Donor Robotic Assisted Kidney Transplantation
NCT06577805
MRI in Renal Transplantation
NCT03705091
Diagnostic Performance of Coronary CT Angiography With CT FFR in Kidney Transplantation Candidates
NCT03248674
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The following assessments will be performed over the course of 4 years for this protocol.
A. Informed Consent will be obtained.
B. A Cimetidine Blocked 24 hour urine collection will be obtained prior to surgery.
C. DETAILED KIDNEY FUNCTION STUDIES will be performed using iothalamate, and PAH at three different times:
1. Prior to surgery for uninephrectomy (the night before to months before surgery)
2. 6 months to 1 year post kidney donation.
3. 4 years after kidney donation.
D. The Structure of the Kidney will also be assessed at three different times during this protocol:
1. Cortical and whole kidney volumes will be determined using the clinical MRI or CT performed routinely for kidney donor evaluation.
2. At the time of surgery, in the operating room: A single wedge biopsy of the kidney will be taken for morphometric and later genetic analysis. \*NOTE: Genetic analysis is for the genetics of ageing not disease. In this procedure, a small wedge kidney biopsy is excised under direct visualization by the transplant surgeon after the kidney has been removed from the donor and before the kidney is transplanted into the recipient. The area of excision is then oversewn and checked for bleeding.
The size (volume) of the Tx kidney will be measured by water displacement in a graduated cylinder immediately before Tx. This volume will be used in our calculations to estimate the number of glomeruli in youthful vs ageing kidneys.
3. A second MRI or CT will be obtained 6 months to 1 year after kidney donation to measure the kidney's overall compensatory growth and increase in cortical volume for comparison with the pre-operative volumes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT angiogram of the remaining kidney.
Kidney Function study using Iothalamate & PAH as clearance markers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jane C. Tan
Associate Professor of Medicine (Nephrology)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bryan D Myers
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Jane C. Tan
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University School of Medicine
Stanford, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB eProtocol #13584
Identifier Type: -
Identifier Source: secondary_id
SPO 45339
Identifier Type: -
Identifier Source: secondary_id
SU-02092009-1778
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.